2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:Ta59,Rates of physician-diagnosed eczema have been increasing among older adults, but little is known regarding the pathophysiologic processes and best treatments in this subgroup. Preliminary data suggest that medications-antihypertensive medications in particular-may contribute to eczematous dermatitis; however, there are limited population-based data on the proportion of eczematous dermatitis diagnoses among older adults that may be attributed to antihypertensive drugs. To determine whether antihypertensive drug use is associated with eczematous dermatitis in older adults. This was a longitudinal cohort study of a population-based sample of individuals 60 years and older without a diagnosis of eczematous dermatitis at baseline. It was conducted at primary care practices participating in The Health Improvement Network in the United Kingdom from January 1, 1994, to January 1, 2015. Data analyses were performed from January 6, 2020, to February 6, 2024. Exposure date by first prescription for an antihypertensive drug within each drug class. Newly active eczematous dermatitis was based on the first date for 1 of the 5 most common eczema codes used in a previously validated algorithm. Among the total study sample of 1 561 358 older adults (mean [SD] age, 67 [9] years; 54% female), the overall prevalence of eczematous dermatitis was 6.7% during a median (IQR) follow-up duration of 6 (3-11) years. Eczematous dermatitis incidence was higher among participants receiving antihypertensive drugs than those who did not (12 vs 9 of 1000 person-years of follow-up). Adjusted Cox proportional hazard models found that participants who received any antihypertensive drugs had a 29% increased hazard rate of any eczematous dermatitis (hazard ratio [HR], 1.29; 95% CI, 1.26-1.31). When assessing each antihypertensive drug class individually, the largest effect size was observed for diuretic drugs (HR, 1.21; 95% CI, 1.19-1.24) and calcium channel blockers (HR, 1.16; 95% CI, 1.14-1.18), and the smallest effect sizes were for angiotensin-converting enzyme inhibitors (HR, 1.02; 95% CI, 1.00-1.04) and β-blockers (HR, 1.04; 95% CI, 1.02-1.06). This cohort study found that antihypertensive drugs were associated with a small increased rate of eczematous dermatitis, with effect sizes largest for calcium channel blockers and diuretic drugs, and smallest for angiotensin-converting enzyme inhibitors and β-blockers. Although additional research is needed to understand the mechanisms underlying the association, these data could be helpful to clinicians to guide management when a patient presents with eczematous dermatitis in older age.31:Td10,ImportanceRates of physician-diagnosed eczema have been increasing among older adults, but little is known regarding the pathophysiologic processes and best treatments in this subgroup. Preliminary data suggest that medications—antihypertensive medications in particular—may contribute to eczematous dermatitis; however, there are limited population-based data on the proportion of eczematous dermatitis diagnoses among older adults that may be attributed to antihypertensive drugs.ObjectivesTo determine whether antihypertensive drug use is associated with eczematous dermatitis in older adults.Design, Settings, and ParticipantsThis was a longitudinal cohort study of a population-based sample of individuals 60 years and older without a diagnosis of eczematous dermatitis at baseline. It was conducted at primary care practices participating in The Health Improvement Network in the United Kingdom from January 1, 1994, to January 1, 2015. Data analyses were performed from January 6, 2020, to February 6, 2024.ExposureExposure date by first prescription for an antihypertensive drug within each drug class.Main outcome measuresNewly active eczematous dermatitis was based on the first date for 1 of the 5 most common eczema codes used in a previously validated algorithm.ResultsAmong the total study sample of 1 561 358 older adults (mean [SD] age, 67 [9] years; 54% female), the overall prevalence of eczematous dermatitis was 6.7% during a median (IQR) follow-up duration of 6 (3-11) years. Eczematous dermatitis incidence was higher among participants receiving antihypertensive drugs than those who did not (12 vs 9 of 1000 person-years of follow-up). Adjusted Cox proportional hazard models found that participants who received any antihypertensive drugs had a 29% increased hazard rate of any eczematous dermatitis (hazard ratio [HR], 1.29; 95% CI, 1.26-1.31). When assessing each antihypertensive drug class individually, the largest effect size was observed for diuretic drugs (HR, 1.21; 95% CI, 1.19-1.24) and calcium channel blockers (HR, 1.16; 95% CI, 1.14-1.18), and the smallest effect sizes were for angiotensin-converting enzyme inhibitors (HR, 1.02; 95% CI, 1.00-1.04) and β-blockers (HR, 1.04; 95% CI, 1.02-1.06).Conclusions and RelevanceThis cohort study found that antihypertensive drugs were associated with a small increased rate of eczematous dermatitis, with effect sizes largest for calcium channel blockers and diuretic drugs, and smallest for angiotensin-converting enzyme inhibitors and β-blockers. Although additional research is needed to understand the mechanisms underlying the association, these data could be helpful to clinicians to guide management when a patient presents with eczematous dermatitis in older age.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Antihypertensive: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Antihypertensive (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Antihypertensive\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Antihypertensive\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Antihypertensive\"}]}}"}}]],["$","$L2f",null,{"title":"Antihypertensive: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Antihypertensive — concise summaries and practical next steps.","papers":[{"doi":"10.1111/head.70199","pmid":"42673606","title":"Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations","journal_title":"Headache: The Journal of Head and Face Pain","journal_issn":"0017-8748","published_at":"2026-08-31T00:00:00.000Z","url":"https://doi.org/10.1111/head.70199","source_score":12,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-04T06:22:20.746Z","updated_at":"2026-09-04T06:22:20.746Z","tags":[{"paper_doi":"10.1111/head.70199","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/head.70199","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1111/head.70199","tag_type":"category","value":"Clinical Neurology","value_numeric":null},{"paper_doi":"10.1111/head.70199","tag_type":"condition","value":"Medication Overuse Headache","value_numeric":null},{"paper_doi":"10.1111/head.70199","tag_type":"condition","value":"Migraine","value_numeric":null},{"paper_doi":"10.1111/head.70199","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1111/head.70199","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1111/head.70199","tag_type":"modality","value":"Antiepileptic","value_numeric":null},{"paper_doi":"10.1111/head.70199","tag_type":"modality","value":"Antihypertensive","value_numeric":null},{"paper_doi":"10.1111/head.70199","tag_type":"modality","value":"CGRP Pathway Antagonist","value_numeric":null},{"paper_doi":"10.1111/head.70199","tag_type":"modality","value":"Migraine Preventive Therapy","value_numeric":null},{"paper_doi":"10.1111/head.70199","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/head.70199","tag_type":"study_design","value":"Clinical Practice Guideline","value_numeric":null},{"paper_doi":"10.1111/head.70199","tag_type":"warning","value":"No specific drugs, effect sizes, or number of included studies are reported in the abstract; tags for specific agents (generics/brands) could not be confirmed and were omitted to avoid speculation.","value_numeric":null},{"paper_doi":"10.1111/head.70199","tag_type":"warning","value":"Study design labeled as 'Clinical Practice Guideline' rather than a primary research design; the companion systematic review is a separate publication.","value_numeric":null},{"paper_doi":"10.1111/head.70199","tag_type":"warning","value":"The guideline is categorized as Level of Evidence 1 based on its AAN systematic-review-backed guideline process, but individual recommendation strengths vary and require consulting the full document and companion systematic review.","value_numeric":null}],"summaries":{"what_studied":"This AAN-process practice guideline evaluated pharmacologic migraine prevention in adults, synthesizing evidence from a systematic review of studies through June 6, 2024, to produce updated recommendations on when to start preventive therapy, which agents to choose, and how to manage special populations (e.g., pregnancy, obesity, hypertension, older adults, medication overuse).","key_result":"The guideline provides evidence-based recommendations covering: initiation criteria for preventive therapy, agent selection by comorbidity (fibromyalgia, obesity, hypertension), special considerations for older adults, pregnancy and lactation safety, sex-related prescribing factors, management of medication overuse, and structured guidance on assessing efficacy, adverse effects, and discontinuation.","limitations":"The abstract does not report specific effect sizes or number of studies included; full appraisal of evidence quality and strength of individual recommendations requires review of the companion systematic review publication.","practice_takeaway":"Clinicians should use this guideline as a structured framework for individualizing migraine preventive therapy—particularly when managing patients with comorbidities or during pregnancy—guided by the specific population-based recommendations. Assessment of treatment efficacy and a clear discontinuation plan should be built into every preventive treatment strategy."}},{"doi":"10.1016/s0140-6736(26)00758-0","pmid":"42385750","title":"Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies","journal_title":"The Lancet","journal_issn":"0140-6736","published_at":"2026-07-01T00:00:00.000Z","url":"https://doi.org/10.1016/s0140-6736(26)00758-0","source_score":159,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-05T13:38:35.221Z","updated_at":"2026-07-05T13:38:35.221Z","tags":[{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"category","value":"Medicine, General & Internal","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"condition","value":"Cardiovascular Risk","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"condition","value":"Hypercholesterolaemia","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"condition","value":"Hypertension","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"condition","value":"Obesity","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"modality","value":"Antihypertensive","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"modality","value":"Lipid-Lowering Agent","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"sample_size","value":"n=978425","value_numeric":978425},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"study_design","value":"Cross-Sectional Survey / Trend Analysis","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"warning","value":"Thailand showed exceptions to the overall trends; findings should be interpreted with caution in Southeast Asian populations.","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"warning","value":"The DOI domain format (s0140-6736(26)00758-0) is consistent with a 2026 Lancet publication — paper is very recently published and has not yet undergone widespread peer scrutiny or replication.","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"warning","value":"The 'practice_changing' impact flag reflects a potential paradigm shift in how metabolic risk is assessed in older adults with obesity, but clinical guidelines have not yet been updated to reflect these findings.","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(26)00758-0","tag_type":"warning","value":"The study design is observational (survey trend analysis), so the link between increased medicine use and risk factor convergence is associative, not causal.","value_numeric":null}],"summaries":{"what_studied":"This multi-country analysis compared systolic blood pressure (SBP), non-HDL cholesterol, HDL cholesterol, and use of antihypertensive and lipid-lowering medicines across BMI categories (normal, overweight, class I, and class II/III obesity) using 110 national health surveys from 7 industrialised countries (Japan, South Korea, Taiwan, Thailand, Finland, England, USA) with 978,425 adults aged 20–79, spanning 1990–2024.","key_result":"Non-HDL cholesterol gap vs. normal BMI narrowed by ~0.05–0.07 mmol/L per decade and SBP gap narrowed by ~0.6–0.7 mmHg per decade in people with obesity, driven largely by greater uptake of lipid-lowering (1.5–1.6 percentage points/decade) and antihypertensive medicines (0.7–2.0 percentage points/decade) in older adults with obesity; in contrast, HDL cholesterol diverged (rising more in normal BMI), and young adults with obesity (<40 years) remained at consistently higher metabolic risk with little convergence.","limitations":"- Observational trend analysis cannot establish causality between medicine use and risk factor convergence.\n- Thailand showed notable exceptions to overall trends, suggesting findings may not generalise uniformly even within the studied countries.\n- Young adults were rarely treated regardless of BMI, leaving an important high-risk group under-characterised.","practice_takeaway":"Older adults with obesity are increasingly being treated to blood pressure and cholesterol levels similar to those of normal-weight peers — clinicians should not assume untreated metabolic risk in this group without checking medicine use. However, young adults with obesity remain undertreated and at higher metabolic risk, warranting proactive screening and earlier intervention."}},{"doi":"10.1001/jamadermatol.2024.1230","pmid":"38776099","title":"Antihypertensive Medications and Eczematous Dermatitis in Older Adults","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2024-05-22T00:00:00.000Z","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11112493","source_score":71,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2024-05-30","doi":"10.1001/jamadermatol.2024.1230","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"71","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2024.1230","title":"Antihypertensive Medications and Eczematous Dermatitis in Older Adults.","journal":"JAMA dermatology","methods":"","results":"Among the total study sample of 1 561 358 older adults (mean [SD] age, 67 [9] years; 54% female), the overall prevalence of eczematous dermatitis was 6.7% during a median (IQR) follow-up duration of 6 (3-11) years. Eczematous dermatitis incidence was higher among participants receiving antihypertensive drugs than those who did not (12 vs 9 of 1000 person-years of follow-up). Adjusted Cox proportional hazard models found that participants who received any antihypertensive drugs had a 29% increased hazard rate of any eczematous dermatitis (hazard ratio [HR], 1.29; 95% CI, 1.26-1.31). When assessing each antihypertensive drug class individually, the largest effect size was observed for diuretic drugs (HR, 1.21; 95% CI, 1.19-1.24) and calcium channel blockers (HR, 1.16; 95% CI, 1.14-1.18), and the smallest effect sizes were for angiotensin-converting enzyme inhibitors (HR, 1.02; 95% CI, 1.00-1.04) and β-blockers (HR, 1.04; 95% CI, 1.02-1.06).","abstract":"$30","keywords":[],"pubmed_id":"38776099","conclusions":"","publication_date":"2024-05-22T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2024.1230","URL":"https://doi.org/10.1001/jamadermatol.2024.1230","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2819258/jamadermatology_ye_2024_oi_240013_1721149710.57994.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"710","type":"journal-article","issue":"7","score":1,"title":["Antihypertensive Medications and Eczematous Dermatitis in Older Adults"],"author":[{"given":"Morgan","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}]},{"given":"Leslie N.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}]},{"given":"Ian","family":"Douglas","sequence":"additional","affiliation":[{"name":"Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom"}]},{"given":"David J.","family":"Margolis","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}]},{"given":"Sinéad M.","family":"Langan","sequence":"additional","affiliation":[{"name":"Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom"}]},{"given":"Katrina","family":"Abuabara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"},{"name":"Division of Epidemiology and Biostatistics, University of California, Berkeley"}]}],"issued":{"date-parts":[[2024,7,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"160","created":{"date-time":"2024-05-22T15:33:01Z","timestamp":1716391981000,"date-parts":[[2024,5,22]]},"indexed":{"date-time":"2025-07-15T03:25:04Z","timestamp":1752549904875,"date-parts":[[2025,7,15]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2819258"}},"subtitle":[],"deposited":{"date-time":"2024-07-17T15:03:22Z","timestamp":1721228602000,"date-parts":[[2024,7,17]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2024,7,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1371/journal.pone.0258219","key":"doi240013r1","year":"2021","issue":"10","author":"Chan","volume":"16","first-page":null,"unstructured":null,"article-title":"The epidemiology of atopic dermatitis in older adults: a population-based study in the United Kingdom.","journal-title":"PLoS One","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2020.2940","key":"doi240013r2","year":"2020","issue":"11","author":"Lam","volume":"156","first-page":"1240","unstructured":null,"article-title":"Inclusion of older adults in randomized clinical trials for systemic medications for atopic dermatitis: a systematic review.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240013r3","year":"2002","issue":"1 Pt 1","author":"Morin","volume":"129","first-page":"19","unstructured":null,"article-title":"Chronic eczematiform eruption in the elderly.","journal-title":"Ann Dermatol Venereol","doi-asserted-by":null},{"DOI":"10.3109/08923973.2013.797992","key":"doi240013r4","year":"2013","issue":"3","author":"Vena","volume":"35","first-page":"447","unstructured":null,"article-title":"Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.","journal-title":"Immunopharmacol Immunotoxicol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2013.282023","key":"doi240013r5","year":"2013","issue":"22","author":"Berger","volume":"310","first-page":"2443","unstructured":null,"article-title":"Pruritus in the older patient: a clinical review.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.sder.2011.04.002","key":"doi240013r6","year":"2011","issue":"2","author":"Berger","volume":"30","first-page":"113","unstructured":null,"article-title":"Pruritus in elderly patients–eruptions of senescence.","journal-title":"Semin Cutan Med Surg","doi-asserted-by":"publisher"},{"DOI":"10.1111/cod.v86.3","key":"doi240013r8","year":"2022","issue":"3","author":"de Groot","volume":"86","first-page":"145","unstructured":null,"article-title":"Systemic allergic dermatitis (systemic contact dermatitis) from pharmaceutical drugs: A review.","journal-title":"Contact Dermatitis","doi-asserted-by":"publisher"},{"DOI":"10.1038/sj.jid.5701018","key":"doi240013r9","year":"2007","issue":"12","author":"Joly","volume":"127","first-page":"2766","unstructured":null,"article-title":"Chronic eczematous eruptions of the elderly are associated with chronic exposure to calcium channel blockers: results from a case-control study.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2013.511","key":"doi240013r10","year":"2013","issue":"7","author":"Summers","volume":"149","first-page":"814","unstructured":null,"article-title":"Chronic eczematous eruptions in the aging: further support for an association with exposure to calcium channel blockers.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2017.03.029","key":"doi240013r11","year":"2017","issue":"8","author":"Abuabara","volume":"137","first-page":"1655","unstructured":null,"article-title":"Development and validation of an algorithm to accurately identify atopic eczema patients in primary care electronic health records from the UK.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0199026","key":"doi240013r12","year":"2018","issue":"6","author":"Pujades-Rodriguez","volume":"13","first-page":null,"unstructured":null,"article-title":"The diagnosis, burden and prognosis of dementia: A record-linkage cohort study in England.","journal-title":"PLoS One","doi-asserted-by":"publisher"},{"DOI":"10.14236/jhi.v19i4.820","key":"doi240013r13","year":"2011","issue":"4","author":"Blak","volume":"19","first-page":"251","unstructured":null,"article-title":"Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates.","journal-title":"Inform Prim Care","doi-asserted-by":"publisher"},{"DOI":"10.3399/bjgp10X483562","key":"doi240013r14","year":"2010","issue":"572","author":"Khan","volume":"60","first-page":"e128","unstructured":null,"article-title":"Validity of diagnostic coding within the General Practice Research Database: a systematic review.","journal-title":"Br J Gen Pract","doi-asserted-by":"publisher"},{"DOI":"10.1002/pds.v16:4","key":"doi240013r15","year":"2007","issue":"4","author":"Lewis","volume":"16","first-page":"393","unstructured":null,"article-title":"Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.","journal-title":"Pharmacoepidemiol Drug Saf","doi-asserted-by":"publisher"},{"DOI":"10.1111/all.2017.72.issue-7","key":"doi240013r17","year":"2017","issue":"7","author":"Hsu","volume":"72","first-page":"1091","unstructured":null,"article-title":"Validation of International Classification of Diseases, Ninth Revision, codes for atopic dermatitis.","journal-title":"Allergy","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.300.6732.1092","key":"doi240013r18","year":"1990","issue":"6732","author":"Chisholm","volume":"300","first-page":"1092","unstructured":null,"article-title":"The Read clinical classification.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.v185.4","key":"doi240013r19","year":"2021","issue":"4","author":"Wan","volume":"185","first-page":"693","unstructured":null,"article-title":"Growing evidence for an association between inflammatory skin disease and chronic kidney disease.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2018.21554","key":"doi240013r21","year":"2019","issue":"6","author":"Haneuse","volume":"321","first-page":"602","unstructured":null,"article-title":"Using the E-value to assess the potential effect of unmeasured confounding in observational studies.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.7326/M16-2607","key":"doi240013r22","year":"2017","issue":"4","author":"VanderWeele","volume":"167","first-page":"268","unstructured":null,"article-title":"Sensitivity analysis in observational research: introducing the E-value.","journal-title":"Ann Intern Med","doi-asserted-by":"publisher"},{"DOI":"10.1080/01621459.1999.10474144","key":"doi240013r23","year":"1999","issue":"446","author":"Fine","volume":"94","first-page":"496","unstructured":null,"article-title":"A proportional hazards model for the subdistribution of a competing risk.","journal-title":"J Am Stat Assoc","doi-asserted-by":"publisher"},{"DOI":"10.1111/cod.2017.77.issue-5","key":"doi240013r25","year":"2017","issue":"5","author":"Yoo","volume":"77","first-page":"339","unstructured":null,"article-title":"Intractable pruritus with chronic eczema in an elderly patient caused by long-term intake of calcium channel blocker.","journal-title":"Contact Dermatitis","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240013r26","year":"2002","issue":"8-9","author":"Touraud","volume":"129","first-page":"1033","unstructured":null,"article-title":"Cross-sensitivity between angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonist.","journal-title":"Ann Dermatol Venereol","doi-asserted-by":null},{"DOI":"10.1111/bjd.v186.2","key":"doi240013r27","year":"2022","issue":"2","author":"Yousaf","volume":"186","first-page":"227","unstructured":null,"article-title":"Association between atopic dermatitis and hypertension: a systematic review and meta-analysis.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1161/HYP.0000000000000047","key":"doi240013r28","year":"2016","issue":"3","author":"Elijovich","volume":"68","first-page":"e7","unstructured":null,"article-title":"Salt sensitivity of blood pressure: a scientific statement from the American Heart Association.","journal-title":"Hypertension","doi-asserted-by":"publisher"},{"DOI":"10.1126/scitranslmed.aau0683","key":"doi240013r29","year":"2019","issue":"480","author":"Matthias","volume":"11","first-page":null,"unstructured":null,"article-title":"Sodium chloride is an ionic checkpoint for human TH2 cells and shapes the atopic skin microenvironment.","journal-title":"Sci Transl Med","doi-asserted-by":"publisher"},{"DOI":"10.1093/pubmed/fdt116","key":"doi240013r30","year":"2014","issue":"4","author":"Mathur","volume":"36","first-page":"684","unstructured":null,"article-title":"Completeness and usability of ethnicity data in UK-based primary care and hospital databases.","journal-title":"J Public Health (Oxf)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2013.10.010","key":"doi240013r32","year":"2014","issue":"2","author":"Eichenfield","volume":"70","first-page":"338","unstructured":null,"article-title":"Guidelines of care for the management of atopic dermatitis: diagnosis and assessment of atopic dermatitis.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/978-981-10-5541-6_18","key":"doi240013r7","year":"2018","issue":null,"author":"Tanei","volume":null,"first-page":"229","unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":null,"key":"doi240013r16","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"The Health Improvement Network (THIN). THIN database. Accessed April 17, 2024. https://www.the-health-improvement-network.com/","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi240013r20","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"UK National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. https://www.nice.org.uk/guidance/ng136","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi240013r24","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"UK National Office of Statistics. Ethnic group by age and sex, England and Wales: Census 2021. Accessed April 16, 2024. https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/ethnicity/articles/ethnicgroupbyageandsexenglandandwales/census2021","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi240013r31","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"UK National Institute for Health and Care Excellence. Starting Hypertensive Drug Treatment. Accessed November 11, 2022. https://www.nice.org.uk/guidance/ng136/chapter/Recommendations#starting-antihypertensive-drug-treatment","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2024,7,1]]},"reference-count":32,"published-online":null,"references-count":32,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":7},"unpaywall":{"doi":"10.1001/jamadermatol.2024.1230","is_oa":true,"title":"Antihypertensive Medications and Eczematous Dermatitis in Older Adults","updated":"2025-07-30T00:59:52+00:00","published_date":"2024-05-22","best_oa_location":{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11112493","pmh_id":"oai:pubmedcentral.nih.gov:11112493","url_for_pdf":null,"url_for_landing_page":"https://www.ncbi.nlm.nih.gov/pmc/articles/11112493"}}},"created_at":"2025-09-20T08:18:50.356Z","updated_at":"2025-09-20T08:25:17.195Z","tags":[{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"condition","value":"Eczematous Dermatitis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"condition","value":"Hypertension","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"modality","value":"Antihypertensive","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"sample_size","value":"n=1,561,358","value_numeric":1561358},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"study_design","value":"Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"warning","value":"Age group tag approximated; the cohort included adults aged 60+, not exclusively 65+.","value_numeric":null}],"summaries":{"what_studied":"A longitudinal cohort of 1,561,358 UK adults aged 60 years and older without baseline eczematous dermatitis examined whether starting antihypertensive drugs (by class) was associated with incident eczematous dermatitis during 1994–2015, with median follow-up of 6 years.","key_result":"Incidence was 12 vs 9 per 1000 person-years among antihypertensive users vs nonusers; any antihypertensive was associated with an adjusted HR 1.29 (95% CI, 1.26–1.31). By class, diuretics HR 1.21 (1.19–1.24) and calcium channel blockers 1.16 (1.14–1.18) showed the largest associations; ACE inhibitors 1.02 (1.00–1.04) and β-blockers 1.04 (1.02–1.06) the smallest.","practice_takeaway":"In older adults with new-onset eczematous dermatitis, review antihypertensive drugs as possible contributors, particularly diuretics and calcium channel blockers; the absolute excess risk was about 3 cases per 1000 person-years."}}],"initialOffset":3,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Antihypertensive"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Antihypertensive"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Antihypertensive"}}}]]

Papers